The U.S. Food and Drug Administration (FDA) is considering comments to their risk-focused draft guidance, “Laser-Assisted In Situ Keratomileusis (LASIK) Lasers-Patient Labeling Recommendations.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback